LBRX

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.

Wall Street analysts forecast LBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LBRX is 46.33 USD with a low forecast of 27.00 USD and a high forecast of 78.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

LB Pharmaceuticals Inc revenue for the last quarter amounts to -5.25M USD, decreased % YoY.

LB Pharmaceuticals Inc. EPS for the last quarter amounts to -3373000.00 USD, decreased % YoY.

LB Pharmaceuticals Inc (LBRX) has 16 emplpoyees as of December 15 2025.

Today LBRX has the market capitalization of 483.85M USD.